Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 879, Issue 21, 2011, Pages 1851-1856

  Sparidans, Rolf W ^a   Martens, Irene ^a   Valkenburg van Iersel, Liselot B J ^b   den Hartigh, Jan ^b   Schellens, Jan H M ^a,c   Beijnen, Jos H ^a,c,d  

^a UTRECHT UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

Human plasma; LC MS MS; Melphalan; Olaparib; PARP inhibitor

Indexed keywords

HUMAN PLASMAS; LC-MS/MS; MELPHALAN; OLAPARIB; PARP-INHIBITOR;

ACETIC ACID; ACETONITRILE; CALIBRATION; ELECTROSPRAY IONIZATION; FORMIC ACID; LIQUID CHROMATOGRAPHY; MASS SPECTROMETERS; MASS SPECTROMETRY; METHANOL; PHARMACOKINETICS; PLASMA (HUMAN); SILICA; SOLVENT EXTRACTION;

NITROGEN PLASMA;

ACETIC ACID; ACETONITRILE; ERLOTINIB; FORMIC ACID; MELPHALAN; OLAPARIB;

ACCURACY; ADULT; ARTICLE; BLOOD SAMPLING; BREAST CARCINOMA; CALIBRATION; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG STABILITY; ELECTROSPRAY; FEMALE; HUMAN; IONIZATION; LIQUID CHROMATOGRAPHY; LIVER METASTASIS; LIVER PERFUSION; METASTASIS; PRIORITY JOURNAL; QUADRUPOLE MASS SPECTROMETRY; QUANTITATIVE ASSAY; STANDARD; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMATOGRAPHY, LIQUID; DRUG STABILITY; FEMALE; HUMANS; LEAST-SQUARES ANALYSIS; MELPHALAN; MIDDLE AGED; NEOPLASMS; PHTHALAZINES; PIPERAZINES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 79959341672     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2011.05.003     Document Type: Article

References (16)

1. Gartner E.M., Burger A.M., Lorusso P.M. Cancer J. 2010, 16:83.
2. Penning T.D. Curr. Opin. Drug Discov. Dev. 2010, 13:577.
3. Sparidans R.W., Silvertand L., Dost F., Rothbarth J., Mulder G.J., Schellens J.H., Beijnen J.H. Biomed. Chromatogr. 2003, 17:458.
4. Musto P., D'Auria F. Expert Opin. Investig. Drugs 2007, 16:1467.
5. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., Mortimer P., Swaisland H., Lau A., O'Connor M.J., Ashworth A., Carmichael J., Kaye S.B., Schellens J.H., de Bono J.S. N. Engl. J. Med. 2009, 361:123.
6. Audeh M.W., Carmichael J., Penson R.T., Friedlander M., Powell B., Bell-McGuinn K.M., Scott C., Weitzel J.N., Oaknin A., Loman N., Lu K., Schmutzler R.K., Matulonis U., Wickens M., Tutt A. Lancet 2010, 376:245.
7. US National Institutes of Health, (accessed 15.02.11). http://clinicaltrials.gov/ct2/results%3Fterm=olaparib.
8. Dungey F.A., Caldecott K.W., Chalmers A.J. Mol. Cancer Ther. 2009, 8:2243.
9. Löser D.A., Shibata A., Shibata A.K., Woodbine L.J., Jeggo P.A., Chalmers A.J. Mol. Cancer Ther. 2010, 9:1775.
10. Davies I.C., Allanson J.P., Causon R.C. Chromatographia 2000, 52(Suppl.):S92.
11. Mirkou A., Vignal B., Cohen S., Guillaumont M., Glehen O., Guitton J. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2009, 877:3089.
12. Center for Drug Evaluation and Research of the U.S. Department of Health and Human Services Food and Drug Administration, 2001 (accessed 26.04.11). http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064964.htm.
13. Shah V.P., Midha K.K., Findlay J.W.A., Hill H.M., Hulse J.D., McGilveray I.J., McKay G., Miller K.J., Patnaik R.N., Powell M.L., Tonelli A., Viswanathan C.T., Yacobi A. Pharm. Res. 2000, 17:1551.
14. Viswanathan C.T., Bansal S., Booth B., DeStefano A.J., Rose M.J., Sailstad J., Shah V.P., Skelly J.P., Swann P.G., Weiner R. Pharm. Res. 2007, 24:1962.
15. Sparidans R.W., Iusuf D., Schinkel A.H., Schellens J.H., Beijnen J.H. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2009, 877:4090.
16. European Medicines Agency, 2009 (accessed 26.04.11). http://www.ema.europa.eu/pdfs/human/ewp/19221709en.pdf.